Skip to main content
OpenTrials

Clinical trial condition

Immunoproliferative Disorders

Explore clinical trials studying Immunoproliferative Disorders. Study availability and eligibility vary by location and protocol.

10,013 public trials 2,032 recruiting studies
Refine in advanced search Browse all conditions

Immunoproliferative Disorders trial results

Completed

A Study of Venetoclax in Combination With Navitoclax and Chemotherapy in Subjects With Relapsed/Refractory Acute Lymphoblastic Leukemia or Relapsed/Refractory Lymphoblastic Lymphoma

NCT03181126

Conditions
Acute Lymphoblastic Leukemia (ALL), Hematologic Diseases, Hemic and Lymphatic Diseases, +10 more
Locations
  • City of Hope /ID# 169029 Duarte, California, United States
  • LPCH Stanford /ID# 163337 Palo Alto, California, United States
  • University of Chicago /ID# 163369 Chicago, Illinois, United States
  • Washington University-School of Medicine /ID# 165689 St Louis, Missouri, United States
View all 15 locations
View Trial Details
Completed

Study of Nivolumab in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) That Have Either Failed or Are Not Eligible for Autologous Stem Cell Transplant (CheckMate 139)

NCT02038933

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +7 more
Locations
  • Mayo Clinic Arizona Phoenix, Arizona, United States
  • Division Of Hematology & Oncology Ctr. For Health Sciences Los Angeles, California, United States
  • Winship Cancer Center Atlanta, Georgia, United States
  • Dana Farber Cancer Institute Boston, Massachusetts, United States
View all 46 locations
View Trial Details
Completed

Trial of Idelalisib in Patients With Relapsed Diffuse Large B-cell Lymphoma

NCT03576443

Conditions
Diffuse Large B Cell Lymphoma, Hemic and Lymphatic Diseases, Immune System Diseases, +9 more
Locations
  • Aarhus University Hospital Aarhus C, Denmark
  • Odense University Hospital Odense, Denmark
  • Halmstad County Hospital Halmstad, Sweden
  • Linkoping University Hospital Linköping, Sweden
View Trial Details
Completed

Sym023 (Anti-TIM-3) in Patients With Advanced Solid Tumor Malignancies or Lymphomas

NCT03489343

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +11 more
Locations
  • South Texas Accelerated Research Therapeutics (START) Midwest Grand Rapids, Michigan, United States
  • The University of Texas MD Anderson Cancer Center Houston, Texas, United States
  • NEXT Oncology San Antonio, Texas, United States
  • Princess Margaret Cancer Centre Toronto, Ontario, Canada
View Trial Details
Completed

Study of UCART19 in Pediatric Patients With Relapsed/Refractory B Acute Lymphoblastic Leukemia

NCT02808442

Conditions
Burkitt Lymphoma, DNA Virus Infections, Epstein-Barr Virus Infections, +16 more
Locations
  • Children's Hospital Los Angeles Los Angeles, California, United States
  • Children's Hospital of Philadelphia Philadelphia, Pennsylvania, United States
  • University of Texas Southwestern Medical Center Dallas, Texas, United States
  • Hôpital Robert-Debré Paris, France
View Trial Details

Related conditions